摘要
目的观察阿托伐他汀联合贝那普利治疗IgA肾病患者的疗效,并探讨其对患者尿蛋白、血肌酐(Scr)水平的影响。方法回顾性分析2014年1月至2017年12月在空军军医大学唐都医院肾脏内科治疗的66例IgA肾病患者的临床资料,根据治疗方法的不同分为对照组和联合治疗组各33例,对照组采用贝那普利治疗,联合治疗组采用阿托伐他汀联合贝那普利治疗,疗程均为3个月。两组患者均于疗程结束后评估治疗疗效,比较两组患者治疗前、治疗1个月、2个月、3个月后的24 h尿蛋白定量和Scr水平。结果联合治疗组患者的治疗总有效率为90.91%,明显高于对照组的66.67%,差异有统计学意义(P<0.05);两组患者治疗前24 h尿蛋白定量水平比较差异无统计学意义(P>0.05);两组患者治疗后24 h尿蛋白定量水平均较治疗前明显降低,治疗1个月、2个月、3个月后,联合治疗组患者的24 h尿蛋白定量水平分别为(0.85±0.76)g、(0.70±0.63)g、(0.60±0.55)g,明显低于对照组的(1.73±0.79)g、(1.61±0.82)g、(1.34±0.76)g,差异均有统计学意义(P<0.05);两组患者治疗前的Scr水平比较差异无统计学意义(P>0.05);两组患者治疗后Scr水平均较治疗前明显降低,治疗1个月、2个月、3个月后,联合治疗组患者的Scr水平分别为(131.90±12.69)mmol/L、(114.73±8.59)mmol/L、(105.65±5.51)mmol/L,明显低于对照组的(146.59±13.74)mmol/L、(135.66±12.88)mmol/L、(128.34±10.79)mmol/L,差异均有统计学意义(P<0.05)。结论阿托伐他汀联合贝那普利治疗IgA肾病可有效降低患者的24 h尿蛋白定量和Scr水平,提高患者的治疗效果。
Objective To observe the efficacy of atorvastatin combined with benazepril in the treatment of IgA nephropathy,and to explore its effect on urine protein and serum creatinine(Scr)levels.Methods The clinical data of 66 patients with IgA nephropathy treated by Department of Nephrology,Tangdu Hospital of Air Force Military Medical University from January 2014 to December 2017 were retrospectively analyzed.According to the different treatment methods,the patients were divided into the control group(n=33)and combined treatment group(n=33).The control group was treated with benazepril,and the combined treatment group was treated with atorvastatin plus benazepril for 3 months.Both groups of patients were evaluated for therapeutic efficacy at the end of the treatment period.The 24-hour urine protein quantitation and Scr levels were compared between the two groups before treatment,1 month,2 months,and 3 months after treatment.Results The total effective rate of the combined treatment group was 90.91%,which was significantly higher than 66.67%of the control group(P<0.05).There was no significant difference in the urine protein level between the two groups before treatment(P>0.05).The urinary protein quantification level of the two groups was significantly lower than that before treatment.The 24-hour urine protein quantitation levels of the patients in the combined treatment group after 1 month,2 months and 3 months of treatment were(0.85±0.76)g,(0.70±0.63)g,(0.60±0.55)g,which was significantly lower than(1.73±0.79)g,(1.61±0.82)g,(1.34±0.76)g of the control group(P<0.05).There was no significant difference in the levels of Scr between the two groups before treatment(P>0.05).The Scr levels in the two groups were significantly lower than those before treatment.One month,2 months,and 3 months after treatment,the Scr levels in the combined treatment group were(131.90±12.69)mmol/L,(114.73±8.59)mmol/L,and(105.65±5.51)mmol/L,which were significantly lower than(146.59±13.74)mmol/L,(135.66±12.88)mmol/L,(128.34±10.79)mmol
作者
赵洁
蒙军平
王薇
周璐
刘佩
ZHAO Jie;MENG Jun-ping;WANG Wei;ZHOU Lu;LIU Pei(Department of Nephrology,Tangdu Hospital of Air Force Military Medical University,Xi'an 710038,Shaanxi,CHINA;Department of Nephrology,Xi'an High-tech Hospital,Xi'an 710075,Shaanxi,CHINA)
出处
《海南医学》
CAS
2019年第22期2876-2878,共3页
Hainan Medical Journal
关键词
阿托伐他汀
贝那普利
IGA肾病
疗效
尿蛋白
血肌酐
Atorvastatin
Benazepril
IgA nephropathy
Efficacy
Urine protein
Serum creatinine
